Amity Institute of Biotechnology, Amity University, Noida, India.
J Biosci. 2020;45(1). doi: 10.1007/s12038-020-00078-7.
Alternate remedies with natural products provides unlimited opportunities for new drug development. These can be either as pure compounds or as standardized set of compounds. The phytochemicals and secondary metabolites are in great demand for screening bioactive compounds and plays an important role towards drug development. Natural products have many advantages over to synthetic chemical drugs. (H. pylori) a Gram-negative bacteria has been classified as Class I carcinogen by World Health Organization in 1994. Current treatment regimens for is 'triple therapy' administrated for two weeks which includes a combination of two antibiotics like Amoxicillin and Clarithromycin and a proton pump inhibitor (PPI) like Lansoprazole, and for 'quadruple therapy' in addition to antibiotics and a PPI, Bismuth is used. Antibiotic resistance can be named as the main factor for failure of treatment of infection. The need of the hour is to develop a herbal remedy that could combat the growth of . Probiotics can also be used as 'feasible' tool for infection management. Present review is an attempt to briefly discuss about the pathogenicity, genetic predisposition, perturbation of gut microbiota due to antibiotic treatment and restoration of healthy gut microbiota with phytochemicals and probiotics.
替代疗法与天然产物为新药开发提供了无限的机会。这些可以是纯化合物，也可以是标准化的化合物组合。植物化学物质和次生代谢物是筛选生物活性化合物的热门选择，对药物开发起着重要作用。天然产物相对于合成化学药物有许多优势。(幽门螺杆菌)于 1994 年被世界卫生组织列为 I 类致癌物。目前的治疗方案是“三联疗法”，持续两周，包括两种抗生素（如阿莫西林和克拉霉素）和一种质子泵抑制剂（PPI）（如兰索拉唑），而“四联疗法”除了抗生素和 PPI 之外，还使用铋剂。抗生素耐药性是导致治疗失败的主要因素。目前的当务之急是开发一种草药疗法来对抗的生长。益生菌也可以作为治疗感染的“可行”工具。本综述试图简要讨论的致病性、遗传易感性、抗生素治疗引起的肠道微生物群失调以及植物化学物质和益生菌对健康肠道微生物群的恢复。
